Article Figures & Data
Tables
- Table 1.
Proportion of Adult 2013 to 2017 Medical Expenditure Panel Survey Respondents Taking Each Medication Regimen by Comorbidity Group
HTN Only HTN-DM HTN-CVD HTN-DM-CVD Number of individuals 8016 3480 2533 1872 Proportion of sample 52.8 (51.5, 54.2) 19.0 (18.0, 20.1) 17.2 (16.1, 18.3) 10.9 (10.2, 11.7) Number of HTN medications 1 48.9 (47.0, 50.8) 37.8 (34.9, 40.7) 33.9 (31.3, 36.6) 23.7 (20.8, 26.8) 2 35.7 (33.9, 37.5) 33.9 (31.3, 36.5) 37.2 (34.4, 40.1) 37.2 (33.8, 40.7) 3 12.7 (11.7, 13.8) 20.8 (18.5, 23.3) 20.1 (17.7, 22.6) 26.2 (23.1, 29.5) 4 2.3 (1.9, 2.8) 6.2 (5.0, 7.7) 7.3 (5.9, 9.1) 10.3 (8.5, 12.6) ≥5 0.4 (0.2, 0.6) 1.4 (0.9, 2.1) 1.5 (1.0, 2.4) 2.6 (1.9, 3.7) 1 Medication ACE/ARB 25.2 (23.8, 26.8) 28.3 (25.6, 31.1) 12.6 (10.8, 14.6) 13.2 (10.8, 16.0) Thiazide 6.2 (5.4, 7.1) 2.4 (1.8, 3.4) 2.4 (1.6, 3.6) 0.9 (0.4, 2.0) Beta-blocker 9.2 (8.2, 10.3) 3.0 (2.3, 4.0) 13.1 (11.2, 15.2) 5.2 (4.1, 6.5) CCB 7.0 (6.3, 7.8) 3.2 (2.4, 4.3) 4.7 (3.7, 5.9) 2.6 (1.7, 4.1) Clonidine/hydralazine/loop/spironolactone 1.3 (1.0 to 1.7) 0.9 (0.5, 1.5) 1.1 (0.7, 1.7) 1.8 (1.2, 2.9) 2 Medications ACE/ARB & CCB 6.0 (5.2, 6.9) 6.6 (5.4, 8.0) 4.8 (3.6, 6.3) 3.9 (2.8, 5.3) ACE/ARB & Beta-Blocker 4.5 (3.9, 5.2) 6.6 (5.3, 8.2) 12.4 (10.6, 14.5) 15.9 (13.5, 18.8) ACE/ARB & Thiazide 15.5 (14.0, 17.1) 12.9 (11.1, 14.9) 5.7 (4.3, 7.4) 6.3 (4.5, 8.5) ACE/ARB & Clonidine/Hydralazine/Loop/Spironolactone 0.8 (0.6, 1.2) 2.3 (1.5, 3.5) 1.7 (1.1, 2.7) 2.7 (1.8, 3.9) CCB & Thiazide 1.6 (1.2, 2.0) 0.7 (0.4, 1.2) 1.0 (0.5, 1.7) 0.3 (0.1, 0.7) CCB & beta-blocker 1.8 (1.4, 2.3) 1.0 (0.7, 1.5) 4.0 (3.0, 5.3) 2.1 (1.3, 3.1) CCB & Clonidine/hydralazine/loop/spironolactone 0.4 (0.3, 0.7) 0.4 (0.2, 0.7) 0.7 (0.4, 1.3) 1.3 (0.7, 2.5) Thiazide & Beta-blocker 4.4 (3.6, 5.2) 2.3 (1.7, 3.1) 3.5 (2.6, 4.6) 1.7 (1.0, 2.8) Thiazide & clonidine/hydralazine/loop/spironolactone 0.2 (0.1, 0.4) 0.1 (0.0, 0.3) 0.3 (0.2, 0.7) 0.1 (0.0, 0.5) Beta-blocker & clonidine/hydralazine/loop/spironolactone 0.6 (0.4, 0.9) 0.8 (0.5, 1.4) 3.1 (2.2, 4.2) 2.8 (1.9, 4.2) Clonidine/hydralazine/loop/spironolactone combination 0.0 (0.0, 0.1) 0.1 (0.0, 0.6) 0.0 (0.0, 0.2) 0.1 (0.0, 0.3) 3 Medications ACE/ARB & CCB & beta-blocker 1.8 (1.4, 2.3) 2.8 (2.1, 3.9) 3.9 (3.0, 5.2) 5.5 (4.1, 7.4) ACE/ARB & CCB & thiazide 4.2 (3.6, 5.0) 6.7 (5.3, 8.5) 2.0 (1.3, 3.0) 3.1 (2.1, 4.4) ACE/ARB & beta-blocker & thiazide 3.6 (3.0, 4.2) 6.0 (4.6, 7.6) 6.4 (5.1, 8.0) 7.3 (5.7, 9.3) ACE/ARB & clonidine/hydralazine/diuretic/spiro & 1 other 1.6 (1.3, 2.0) 3.3 (2.6, 4.3) 4.9 (3.9, 6.3) 7.6 (5.9, 9.6) CCB & beta-blocker & thiazide 0.8 (0.6, 1.2) 0.9 (0.4, 2.0) 1.0 (0.6, 1.8) 0.6 (0.3, 1.1) Remaining 3 medication combinations without ACE/ARB 0.6 (0.4, 0.9) 0.9 (0.5, 1.7) 1.7 (1.1, 2.7) 2.2 (1.4, 3.4) 4 or More Medications ACE/ARB included combinations 2.5 (2.1, 3.1) 7.1 (5.7, 8.8) 8.1 (6.6, 9.9) 11.9 (9.8, 14.34) 4 or more medication classes without ACE/ARB 0.2 (0.1, 0.3) 0.5 (0.3, 0.9) 0.8 (0.4, 1.4) 1.1 (0.5, 2.2) ACE, angiotensin converting-enzyme; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker; CVD, cardiovascular disease; DM, diabetes mellitus; HTN, hypertension.
There were 15,901 hypertensive adults without heart failure taking hypertension medication in the Medical Expenditure Panel Survey from 2013 through 2015. We divided our sample into four different comorbidity groups based on hypertension, diabetes, and cardiovascular disease (coronary heart disease or stroke) diagnoses. We then calculated the proportion of adults taking different single-drug and multi-drug hypertension medications regimens in each comorbidity group. Numbers in parentheses represent upper and lower limits of 95% CIs.
In this issue
